Clinical Trial Update: Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating regorafenib for second-line treatment of C-kit mutated malignant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Regorafenib (regorafenib)

Snippet

Sponsor: Yonsei University | Conditions: Melanoma | Phase 2 | Status: UNKNOWN